US20040053976A1 - Terminally-branched polymeric linkers and polymeric conjugates containing the same - Google Patents
Terminally-branched polymeric linkers and polymeric conjugates containing the same Download PDFInfo
- Publication number
- US20040053976A1 US20040053976A1 US10/638,031 US63803103A US2004053976A1 US 20040053976 A1 US20040053976 A1 US 20040053976A1 US 63803103 A US63803103 A US 63803103A US 2004053976 A1 US2004053976 A1 US 2004053976A1
- Authority
- US
- United States
- Prior art keywords
- substituted
- group
- alkyls
- compound
- heteroalkyls
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 C.C.C.C.CC(C)(C)C.[1*]CC([2*])([3*])/C(=[Y]\[Y])N(C)C.[4*]C([5*])(C)CC([7*])([8*])C(B)=[Y].[4*]C([5*])(C)CC([7*])([8*])C(B)=[Y] Chemical compound C.C.C.C.CC(C)(C)C.[1*]CC([2*])([3*])/C(=[Y]\[Y])N(C)C.[4*]C([5*])(C)CC([7*])([8*])C(B)=[Y].[4*]C([5*])(C)CC([7*])([8*])C(B)=[Y] 0.000 description 34
- GETQZCLCWQTVFV-UHFFFAOYSA-N CN(C)C Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 6
- ARXWBRMTBOPAJQ-UHFFFAOYSA-N BB(B)N(C)C Chemical compound BB(B)N(C)C ARXWBRMTBOPAJQ-UHFFFAOYSA-N 0.000 description 2
- FVVIUWULZHTOQL-UHFFFAOYSA-N CNC(=O)CC(CC(=O)NC)(CC(=O)NC)NC(=O)COCCOCC(=O)NC(CC(=O)NC)(CC(=O)NC)CC(=O)NC.CNC(=O)CC(NC(=O)COCCOCC(=O)NC(CC(=O)NC)C(=O)NC)C(=O)NC.CNC(=O)CN(CC(=O)NC)C(=O)CC(=O)NCCOCCNC(=O)CC(=O)N(CC(=O)NC)CC(=O)NC.CNC(=O)CN(CC(=O)NC)C(=O)COCCOCC(=O)N(CC(=O)NC)CC(=O)NC.CNC(=O)CN(CC(=O)NC)C(=O)OCCOC(=O)N(CC(=O)NC)CC(=O)NC.CNC(=O)COCC(COCC(=O)NC)NC(=O)COCCOCC(=O)NC(COCC(=O)NC)COCC(=O)NC.CNC(=O)COCCN(CCOCC(=O)NC)C(=O)OCCOC(=O)N(CCOCC(=O)NC)CCOCC(=O)NC.COC(=O)CN(CC(=O)OC)C(=O)CN(CC(=O)N(CC(=O)OC)CC(=O)OC)C(=O)COCCOCC(=O)N(CC(=O)N(CC(=O)OC)CC(=O)OC)CC(=O)N(CC(=O)OC)CC(=O)OC Chemical compound CNC(=O)CC(CC(=O)NC)(CC(=O)NC)NC(=O)COCCOCC(=O)NC(CC(=O)NC)(CC(=O)NC)CC(=O)NC.CNC(=O)CC(NC(=O)COCCOCC(=O)NC(CC(=O)NC)C(=O)NC)C(=O)NC.CNC(=O)CN(CC(=O)NC)C(=O)CC(=O)NCCOCCNC(=O)CC(=O)N(CC(=O)NC)CC(=O)NC.CNC(=O)CN(CC(=O)NC)C(=O)COCCOCC(=O)N(CC(=O)NC)CC(=O)NC.CNC(=O)CN(CC(=O)NC)C(=O)OCCOC(=O)N(CC(=O)NC)CC(=O)NC.CNC(=O)COCC(COCC(=O)NC)NC(=O)COCCOCC(=O)NC(COCC(=O)NC)COCC(=O)NC.CNC(=O)COCCN(CCOCC(=O)NC)C(=O)OCCOC(=O)N(CCOCC(=O)NC)CCOCC(=O)NC.COC(=O)CN(CC(=O)OC)C(=O)CN(CC(=O)N(CC(=O)OC)CC(=O)OC)C(=O)COCCOCC(=O)N(CC(=O)N(CC(=O)OC)CC(=O)OC)CC(=O)N(CC(=O)OC)CC(=O)OC FVVIUWULZHTOQL-UHFFFAOYSA-N 0.000 description 2
- VFPBUJJMHNQEHR-HLHVGWJZSA-N *.B.C.C.CC[C@@]1(O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.[2HH] Chemical compound *.B.C.C.CC[C@@]1(O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.[2HH] VFPBUJJMHNQEHR-HLHVGWJZSA-N 0.000 description 1
- UVPNVPIPHMSFHS-XJDYSXCLSA-N CC1=CC(=O)N(O)C(C2CCCCC2)=C1.COC1=CC([C@@H]2C3=CC4=C(C=C3[C@H](O)[C@H]3COC(=O)C23)OCO4)=CC(OC)=C1OC.NC1=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)C=C1.NC1=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)C=C1.OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1 Chemical compound CC1=CC(=O)N(O)C(C2CCCCC2)=C1.COC1=CC([C@@H]2C3=CC4=C(C=C3[C@H](O)[C@H]3COC(=O)C23)OCO4)=CC(OC)=C1OC.NC1=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)C=C1.NC1=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)C=C1.OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1 UVPNVPIPHMSFHS-XJDYSXCLSA-N 0.000 description 1
- HMNZDWSWFZRLMT-HSZRJFAPSA-N CC[C@](C)(C(C=C1N2Cc3cc(cccc4)c4nc13)=C(CO1)C2=O)/C1=[O]\CNC Chemical compound CC[C@](C)(C(C=C1N2Cc3cc(cccc4)c4nc13)=C(CO1)C2=O)/C1=[O]\CNC HMNZDWSWFZRLMT-HSZRJFAPSA-N 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N CNC Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N NC(CO)(CO)CO Chemical compound NC(CO)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F283/00—Macromolecular compounds obtained by polymerising monomers on to polymers provided for in subclass C08G
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pregnancy & Childbirth (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polyethers (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Abstract
E1-4 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy C1-6 heteroalkoxy,
and at least one of E1-4 includes a B moiety, wherein B is a leaving group, OH, a residue of a hydroxyl- or amino-containing moiety or
wherein J1 is the same as J, or another member of the group defining J and E5 is the same as E1-4, or another member of the group defining E1-4,
Y1-2 are independently O, S or NR9;
M is a heteroatom selected from either X or Q; wherein X is an electron withdrawing group and Q is a moiety containing a free electron pair positioned three to six atoms from C(═Y2);
R2-5 and R7-9 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy;
(m1) and (m2) are independently zero or one;
(n1), (n2), (p1), (p2) and (q) are independently zero or a positive integer;
Z is an electron withdrawing group; and
Description
- This application is a continuation-in-part of U.S. patent application Ser. No. 09/062,305 filed Apr. 17, 1998, the contents of which are incorporated herein by reference.
- The present invention relates to new types of terminally-activated polymeric materials which are useful in forming long-acting conjugates of bioactive materials. In particular, the invention relates to polymeric-based conjugates having increased therapeutic payloads and methods of preparing the same.
- Over the years, several methods of administering biologically-effective materials to mammals have been proposed. Many medicinal agents are available as water-soluble salts and can be included in pharmaceutical formulations relatively easily. Problems arise when the desired medicinal agent is either insoluble in aqueous-fluids or is rapidly degraded in vivo. Alkaloids are often especially difficult to solubilize.
- One way to solubilize medicinal agents is to include them as part of a soluble prodrug. Prodrugs include chemical derivatives of a biologically-active parent compound which, upon administration, eventually liberate the parent compound in vivo. Prodrugs allow the artisan to modify the onset and/or duration of action of an agent in vivo and can modify the transportation, distribution or solubility of a drug in the body. Furthermore, prodrug formulations often reduce the toxicity and/or otherwise overcome difficulties encountered when administering pharmaceutical preparations. Typical examples of prodrugs include organic phosphates or esters of alcohols or thioalcohols. SeeRemington's Pharmaceutical Sciences, 16th Ed., A. Osol, Ed. (1980), the disclosure of which is incorporated by reference herein.
- Prodrugs are often biologically inert or substantially inactive forms of the parent or active compound. The rate of release of the active drug, i.e. the rate of hydrolysis, is influenced by several factors but especially by the type of bond joining the parent drug to the modifier. Care must be taken to avoid preparing prodrugs which are eliminated through the kidney or reticular endothelial system, etc. before a sufficient amount of hydrolysis of the parent compound occurs.
- Incorporating a polymer as part of a prodrug system has been suggested to increase the circulating life of a drug. However, it has been determined that when only one or two polymers of less than about 10,000 daltons each are conjugated to certain biologically active substances such as alkaloid compounds, the resulting conjugates are rapidly eliminated in vivo, especially if a somewhat hydrolysis-resistant linkage is used. In fact, such conjugates are so rapidly cleared from the body that even if a hydrolysis-prone ester linkage is used, not enough of the parent molecule is regenerated in vivo to be therapeutic.
- Camptothecin and related biologically active analogs are often poorly water soluble and are examples of substances which would benefit from PEG prodrug technology. A brief overview of some previous work in the field is presented below.
- Ohya, et al.,J. Bioactive and Compatible Polymers Vol. 10 January, 1995, 51-66, disclose doxorubicin-PEG conjugates which are prepared by linking the two substituents via various linkages including esters. The molecular weight of the PEG used, however, is only about 5,000 at most. Thus, the in vivo benefits are not fully realized because the conjugates are substantially excreted prior to sufficient linkage hydrolysis.
- U.S. Pat. No. 4,943,579 discloses certain simple 20(S)-camptothecin amino acid esters in their salt forms as water soluble prodrug. The reference does not, however, disclose -using an amino acid as part of a linkage which would attach the alkaloid to a relatively high molecular weight polymer in order to form a prodrug. As evidenced by the data provided in Table 2 of the '579 patent, hydrolysis is rapid. Consequently, at physiologic pH, the insoluble base is rapidly generated after injection, binds to proteins and is quickly eliminated from the body before a therapeutic effect can be achieved. A related effort was directed to developing a water-soluble camptothecin sodium salt. Unfortunately, the water-soluble sodium salt of camptothecin remained too toxic for clinical application (Gottlieb et al,. 1970Cancer Chemother. Rep. 54, 461; Moertel et al,. 1972 ibid, 56, 95; Gottlieb et al., 1972ibid, 56, 103).
- Commonly-assigned PCT publication WO96/23794 describes bis-conjugates in which one equivalent of the hydroxyl-containing drug is attached to each terminal of the polymer. In spite of this advance, techniques which would, further increase, the payload of the polymer have been sought.
- Thus, there continues to be a need to provide additional technologies for forming prodrugs of therapeutic moieties such as camptothecin and related analogs. The present invention addresses this need.
-
-
-
- wherein J1 is the same as J, or another member of the group defining J and E5 is the same as E1-4, or another member of the group defining E1-4;
- Y1-2 are independently O or S;
- M is a heteroatom selected from either X or Q; wherein X is an electron withdrawing group and Q is a moiety containing a free electron pair positioned three to six atoms from C(═Y2);
- R2-5 and R7-8 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy;
- (m1) and (m2) are independently zero or one;
- (n1), (n2), (p1), (p2) and (q) are independently zero or a positive integer;
- Z is an electron withdrawing group; and
- R1 is a polymeric residue such as a water-soluble polyalkylene oxide, preferably having a molecular weight of at least about 20,000 Daltons.
-
- where all variables are as previously defined. The bifunctional compounds are thus formed when the polymeric residue (R1) includes both an alpha and an omega terminal linking group so that two, four or more equivalents of a biologically active agent, drug or protein, designated herein as B, can be delivered. Multifunctional compounds represented by the formula (I′) are preferred.
- When B is a residue of a hydroxyl-containing moiety or an amine-containing moiety, each B is attached via a hydrolyzable linkage which attaches to the polymer residue terminus.
- Examples of hydroxyl-containing moieties for which one or more of improved aqueous solubility, decreased antigenicity, prodrug and/or controlled release delivery is desired include chemotherapeutic compound residues such as anti-fungal compounds, including triazoles, echinocandins, pneumocandins, etc, anti-cancer compounds such as camptothecin, paclitaxel, etoposide, anti-cancer platinum compounds containing OH groups, floxuridine or podophyllotoxin. In still further embodiments, other oncolytic agents, non-oncolytic agents such as anti-inflammatory agents, including steroidal compounds, as well as therapeutic low molecular weight peptides such as insulin are also contemplated.
- Examples of amine-containing moieties for which one or more of improved aqueous solubility, decreased antigenicity, prodrug and/or controlled release delivery is desired include antimetabolites such as Ara-C or gemcitabine.
- Alternatively, B can be a leaving-group such as N-hydroxybenzotriazolyl, N-hydroxyphthalimidyl, halogen, p-nitrophenoxy, imidazolyl, N-hydroxysuccinimidyl, thiazolidyl thione, or other activating groups.
- For purposes of the present invention, the term “residue” shall be understood to mean that portion of a biologically active compound which remains after the biologically active compound has undergone a substitution reaction in which the prodrug carrier portion has been attached.
- For purposes of the present invention, the term“alkyl” shall be understood to include straight, branched, substituted, e.g. halo-, alkoxy-, and nitro- C1-12 alkyls, C3-8 cycloalkyls or substituted cycloalkyls, etc.
- For purposes of the present invention, the term “substituted” shall be understood to include adding or replacing one or more atoms contained within a functional group or compound with one or more different atoms.
- The term “sufficient amounts” for purposes of the present invention shall mean an amount which achieves a therapeutic effect as such effect is understood by those of ordinary skill in the art.
- One of the chief advantages of the compounds of the present invention is that the prodrugs have a higher payload per unit of polymer than previous techniques. Another advantage is that the linkers achieve a proper balance between the rate of parent drug-polymer linkage hydrolysis and the rate of clearance of prodrug from the body. The linkages between the polymer and the parent compounds, also referred to herein as a biologically-active nucleophiles, hydrolyze at a rate which allows a sufficient amount of the parent molecules to be released in vivo before clearance of the prodrug from the plasma or body. The high payload polymeric conjugates of the present invention are thus unique delivery systems which can contain up to four or a greater number of molecules of a drug.
- Methods of making and using the compounds and conjugates described herein are also provided.
- FIGS. 1a, 1 b, 2 a, 2 b schematically illustrate methods of forming compounds of the present invention.
- FIGS.3-9 schematically illustrate compounds synthesized in the Examples.
-
-
-
- wherein J1 is the same as J, or another member of the group defining J; optionally when J1 is the same as J, m1, n1 and p1, etc. are different from those used in J; and E5 is the same as E1-4, or another member of the group defining E1-4;
- Y1-2 are independently O or S;
- M is a heteroatom selected from either X or Q; wherein X is an electron withdrawing group and Q is a moiety containing a free electron pair positioned three to six atoms from C(═Y2);
- R2-5 and R7-8 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy;
- (m1) and (m2) are independently zero or one;
- (n1), (n2), (p1), (p2) and (q) are independently zero or a positive integer;
- Z is an electron withdrawing group; and
- R1 is a polymeric residue.
-
- wherein all variables are as defined above.
- Within Formula (I), Y1 and Y2 are preferably oxygen, R2-5 are preferably H or methyl, (n) is 1 or 2, (p) is 1 and (q) is 1.
-
- where all variables are as previously defined.
- 1. The Electron Withdrawing Groups X and Z
- Within the Formula (I), X and Z are variables which represent electron withdrawing groups. In particular, X and Z can be independently selected from moieties such as O, S, SO, SO2, C(═Y3) wherein Y3 is either O or S, and NR6 wherein R6 is one of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls. C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls and substituted C1-6 heteroalkyls, branched alkyls, aryls, substituted aryls, C1-6 alkyl aralkyls, heteroalkyls, substituted heteroalkyls or substituted C1-6 alkyls such as carboxyalkyls, aminoalkyls, dialkylaminos, hydroxyalkyls or mercaptoalkyls, to name but a few. Preferably, X is either O or NR6 and R6 is preferably H. In preferred embodiments, when X is oxygen, the oxygen is provided as the terminal portion of the PEG polymer. The terminal oxygen can be substituted to provide the other X moieties described herein using techniques apparent to those of ordinary skill without undue experimentation.
- 2. O Portion of the Linker
-
- Preferably, R9 is H, a C1-6 alkyl or substituted C1-6 alkyl. The free electron pair can be anywhere along the Q moiety as long as the defined spacing between the free electron pair and the oxygen is maintained. In these embodiments, R1 is attached to Q via NR9, O, or S. Thus, Q assists hydrolysis of the prodrug linkage by anchimeric assistance because the free electron pair moiety can generate a three- to six-membered, but preferably five-membered, ring by-product upon hydrolysis of the preferably ester linkage.
- 3. Drug Generation Via Hydrolysis of the Prodrug
- The prodrug compounds of the present invention are designed so that the t1/2 of hydrolysis is <t1/2 elimination in plasma.
- The linkages included in the compounds, have hydrolysis rates in the plasma of the mammal being treated which is short enough to allow sufficient amounts of the parent compounds, i.e. the amino- or hydroxyl-containing bioactive compound, to be released prior to elimination. Some preferred compounds of the present invention, i.e. those in which (n) is 1, have a t1/2 for hydrolysis in plasma ranging from about 5 minutes to about 12 hours. Preferably, the compositions have a plasma t1/2 hydrolysis ranging from about 0.5 to about 8 hours and most preferably from about 1 to about 6 hours.
-
- wherein all variables are the same as defined above. Suitable examples of such polymers include polyalkylene oxides such as polyethylene glycols. The general formula for PEG and its derivatives, i.e.
- A2′—O—(CH2CH2O)x—(CH2)n3—A2′
- where (x) represents the degree of polymerization (i.e. from about 10 to about 2,300) or number of repeating units in the polymer chain and is dependent on the molecular weight of the polymer, (n3) is zero or a positive integer, (A2) is a capping group as defined herein, i.e. an, amino, carboxy, halo, C1-6 alkyl or others activating group and (A′2) is the same as (A2) or another (A2) moiety. Also useful are polypropylene glycols, branched PEG derivatives such as those described in commonly-assigned U.S. Pat. No. 5,643,575, “star-PEG's” and multi-armed PEG's such as those-described in Shearwater Polymers, Inc. catalog “Polyethylene Glycol Derivatives 1997-1998”. The disclosure of each of the foregoing is incorporated herein by reference. It will be understood that the water-soluble polymer can be functionalized for attachment to the linkage via M, X or Q herein. As an example, the PEG portion of the inventive compositions can be one of the following non-limiting compounds:
- —C(═Y)—(CH2)n3—O—(CH2CH2O)x—A2, —C(═Y)—Y—(CH2)n3—O—(CH2CH2O)x—A2, and —C(═Y)—NR6—(CH2)n3—O—(CH2CH2O)x—A2,
- where Y is O or S and A2, R6, (n3) and (x) are as defined above.
- In many aspects of the present invention, bis-activated polyethylene glycols are preferred when di-substituted polymer conjugates are desired. Alternatively, polyethylene glycols (PEG's), mono-activated, C1-4 alkyl-terminated PAO's such as mono-methyl-terminated polyethylene glycols (mPEG's) are preferred when mono-substituted polymers are desired.
- In order to provide the desired hydrolyzable linkage, mono- or di-acid activated polymers such as PEG acids or PEG diacids can be used as well as mono- or di-PEG amines and mono- or di-PEG diols. Suitable PAO acids can be synthesized by first converting mPEG-OH to an ethyl ester followed by saponification. See also Gehrhardt, H., et al. Polymer Bulletin 18: 487 (1987) and Veronese, F. M., et al., J. Controlled
Release 10; 145 (1989). Alternatively, the PAO-acid can be synthesized by converting mPEG-OH into a t-butyl ester followed by acid cleavage. See, for example, commonly assigned U.S. Pat. No. 5,605,976. The disclosures of each of the foregoing are incorporated by reference herein. - Although PAO's and PEG's can vary substantially in number average molecular weight, polymers ranging from about 2,000 to about 100,000 are usually selected for the purposes of the present invention. Molecular weights of from about 5,000 to about 50,000 are preferred and 20,000 to about 40,000 are particularly preferred. The number average molecular-weight of the polymer selected for inclusion in the prodrug must be sufficient so as to provide sufficient circulation of the prodrug before hydrolysis of the linker. Within the ranges provided above, polymers having molecular weight ranges of at least 20,000 are preferred fee chemotherapeutic and organic moieties. In the case of some nucleophiles such as certain proteins, enzymes and the like, the number average molecular weight of the polymeric residue can range from about 2,000 to about 20,000.
- The polymeric substances included herein are preferably water-soluble at room temperature. A non-limiting list of such polymers include polyalkylene oxide homopolymers such as polyethylene glycol (PEG) or polypropylene glycols, polyoxyethylenated polyols, copolymers thereof and block copolymers thereof, provided that the water solubility of the block copolymers is maintained.
- As an alternative to PAO-based polymers, effectively non-antigenic materials such as dextran, polyvinyl alcohols, carbohydrate-based polymers, hydroxypropylmethacrylamide (HPMA), and copolymers thereof etc. and the like can be used if the same type of activation is employed as described herein for PAO's such as PEG. Those of ordinary skill in the art will realize that the foregoing list is merely illustrative and that all polymeric materials having the qualities described herein are contemplated. For purposes of the present invention, “effectively non-antigenic” and “substantially non-antigenic” shall be understood to include all polymeric materials understood in the art as being substantially non-toxic-and not eliciting an appreciable immune response in mammals.
- It will be clear from the foregoing that other polyalkylene oxide derivatives of the foregoing, such as the polypropylene glycol acids, etc., as well as other bifunctional linking groups are also contemplated.
- 1. Residues of Hydroxyl-containing Compounds
- a. Camptothecin and Related Topoisomerase I Inhibitors
-
- From this core structure, several known analogs have been prepared. For example, the A ring in either or-both of the 10- and 11-positions can be substituted with an OH. The A ring can also be substituted in the 9-position with a straight or branched C1-30 alkyl or C1-17 alkoxy, optionally linked to the ring by a heteroatom i.e.—O or S. The B ring can be substituted in the 7-position with a straight or branched C1-30 alkyl or substituted alkyl-, C5-8 cycloakyl, C1-30 alkoxy, phenyl alkyl, etc., alkyl carbamate, alkyl carbazides, phenyl hydrazine derivatives, amino-, aminoalkyl-, aralkyl, etc. Other substitutions are possible in the C, D and E rings. See, for example, U.S. Pat. Nos. 5,004,758; 4,943,579; Re 32,518, the contents of which are incorporated herein by reference. Such derivatives can be made using known synthetic techniques without undue experimentation. Preferred carptothecin derivatives for use herein include those which include a 20-OH or another OH moiety which is capable of reacting directly with activated forms of the polymer transport systems described herein or to the linking moiety intermediates, e.g. iminodiacetic acid, etc., which are then attached to a polymer such as PEG. Reference to camptothecin analogs herein has been made for purposes of illustration and not limitation.
- b. Taxanes and Paclitaxel Derivatives
- One class of compounds included in the prodrug compositions of the present invention is taxanes. For purposes of the present invention, the term “taxane” includes all compounds within the taxane family of terpenes. Thus, taxol (paclitaxel), 3′-substituted tert-butoxy-carbonyl-amine derivatives (taxoteres) and the like as well as other analogs which are readily synthesized using standard organic techniques or are available from commercial sources such as Sigma. Chemical of St. Louis, Mo. are within the scope of the present invention. Representative taxanes are shown below.
- These derivatives have been found to be effective anti-cancer agents. Numerous studies indicate that the agents have activity against several malignancies. To date, their use has been severely limited by, among other things, their short supply, poor water solubility and a tendency to cause hypersensitivity. It is to be understood that other taxanes including the 7-aryl carbamates and 7-carbazates disclosed in commonly assigned U.S. Pat. Nos. 5,622,986 and 5,547,981 can also be included in the prodrugs of the present invention. The contents of the foregoing U.S. patents are incorporated herein by reference. The only limitation on the taxane is that it must be capable of undergoing a hydroxyl based substitution reaction such as at the 2′ position. Paclitaxel, however, is a preferred taxane.
- C. Additional Biologically-Active Moieties
-
- The parent compounds selected for prodrug forms need not be substantially water-insoluble, although the polymer-based prodrugs of the present invention are especially well suited for delivering such water-insoluble compounds. Other useful parent compounds include, for example, certain low molecular weight biologically active proteins, enzymes and peptides, including peptido glycans, as well as other anti-tumor agents; cardiovascular agents such as forskolin; anti-neoplastics such as combretastatin, vinblastine, doxorubicin, maytansine, etc.; anti-infectives such as vancomycin, erythromycin, etc.; anti-fungals such as nystatin, amphotericin B, triazoles, papulocandins, pneumocandins, echinocandins, polyoxins, nikkomycins, pradimicins, benanomicins, etc. see, “Antibiotics That Inhibit Fungal Cell Wall Development”Annu. Rev. Microbiol. 1994, 48:471-97, the, contents of which are incorporated herein by reference; anti-anxiety agents, gastrointestinal agents, central nervous system-activating agents, analgesics, fertility or contraceptive agents, anti-inflammatory agents, steroidal agents, anti-urecemic agents, cardiovascular agents, vasodilating agents, vasoconstricting agents and the like.
- The foregoing is illustrative of the biologically active moieties which are suitable for the prodrugs of the present invention. It is to be understood that those biologically active materials not specifically mentioned but having suitable ester-forming groups, i.e. hydroxyl moieties, are also intended and are within the scope of the present invention. It is also to be understood that the prodrug conjugates of the present invention may also include minor amounts of compounds containing not only one equivalent of drug and polymer but also a moiety which does not effect. bioactivity in vivo. For example, it has been found that in some instances, in spite of reacting diacids with drug molecules having a single linkage point, the reaction conditions do not provide quantitative amounts of prodrugs with two equivalents of drug per polymer. By-products of the reactants can sometimes be formed such as acyl ureas if carbodiimides are used.
- 2. Residues of Amine-containing Compounds
- In some aspects of the invention, B is a residue of an amine-containing compound, a non-limiting list of such suitable compounds include residues of organic compounds, enzymes, proteins, polypeptides, etc. Organic compounds include, without limitation, moieties such as anthracycline compounds including daunorubicin, doxorubicin; p-aminoaniline mustard, melphalan, Ara-C (cytosine arabinoside) and related anti-metabolite compounds, e.g., gemcitabine, etc. Alternatively, B can be a residue of an amine-containing cardiovascular agent, anti-neoplastic, anti-infective, anti-fungal such as nystatin and amphotericin B, anti-anxiety agent, gastrointestinal agent, central nervous system-activating agent, analgesic, fertility agent, contraceptive agent, anti-inflammatory agent, steroidal agent, anti-urecemic agent, vasodilating agent, vasoconstricting agent, etc.
- In a preferred aspect of the invention, the amino-containing compound is a biologically active compound that is suitable for medicinal or diagnostic use in the treatment of animals, e.g., mammals, including humans, for conditions for which such treatment is desired. The foregoing list is meant to be illustrative and not limiting for the compounds which can be modified. Those of ordinary skill will realize that other such compounds can be similarly modified without undue experimentation. It is to be understood that those biologically active materials not specifically mentioned but having suitable amino-groups are also intended and are within the scope of the present invention.
- The only limitations on the types of amino-containing molecules suitable for inclusion herein is that there is available at least one (primary or secondary) amine-containing position which can react and link with a carrier portion and that there is not substantial loss of bioactivity after the prodrug system releases and regenerates the parent compound.
- It is noted that parent compounds suitable for incorporation into the prodrug compositions of the invention, may themselves be substances/compounds which are not active after hydrolytic release from the linked composition, but which will become active after undergoing a further chemical process/reaction. For example, an anticancer drug that is delivered to the bloodstream by the double prodrug transport system, may remain inactive until entering a cancer or tumor cell, whereupon it is activated by the cancer or tumor cell chemistry, e.g., by an enzymatic reaction unique to that cell.
- The prodrugs of the present invention can be prepared in at least two general fashions. In the first method, schematically illustrated in FIGS. 1a (symmetrical branches) and 1 b (asymmetrical branches), the polymer residue is attached to the branching groups and thereafter the biologically active moiety or drug, e.g. Drug-OH or Drug-NH2 is attached to the polymeric terminal branches. In the second method, the biologically active moiety or drug, e.g. Drug-OH or Drug-NH2 is attached to the branching groups and thereafter, the resultant intermediate is attached to the polymeric residue. FIGS. 1a and 2 a schematically illustrate methods in which symmetrical branches are used. Methods in which asymmetrical branches are used are illustrated in FIGS. 1b and 2 b.
- 1. First Method
-
-
- where B4 is OH and all other variables are as defined above.
-
-
- wherein M, (C) and R1-3 are as defined above, Y2 is O or S and B2 is a leaving group which is capable of reacting with an unprotected amine, such as an activated carbonate moiety like p-nitrophenyl or succinimidyl carbonate; a thiazolidine thione or other art recognized activating group to form (IXc). In the final synthesis step, a biologically active moiety having an available OH or N group is reacted with (IXc) to form the polymeric transport form (IXd).
- Attachment of the B moiety, e.g. Drug-OH or Drug-NH2 is preferably carried out in the presence of a coupling agent. A non-limiting list of suitable coupling agents include 1,3-diisopropylcarbodiimide (DIPC), any suitable dialkyl carbodiimides, 2-halo-1-alkyl-pyridinium halides, (Mukaiyama reagents), 1-(3 dimethylaminopropyl)-3-ethyl carbodiimide (EDC), propane phosphonic acid cyclic anhydride (PPACA) and phenyl dichlorophosphates, etc. which are available, for example from commercial sources such as Sigma-Aldrich Chemical, or synthesized using known techniques.
-
- where at least one of (m2), (n2) and (p2) is not the same as (m1), (n1) and (p1), respectively. While not illustrated in FIG. 1a and 1 b, the reaction scheme for attaching biologically active moieties having an available NH2 group such as a protein or enzyme proceeds in a similar manner. All-variables shown in the schematics of FIGS. 1a and 1 b are the same as that previously defined herein.
- Preferably the substituents are reacted in an inert solvent such as methylene chloride, chloroform, toluene, DMF or mixtures thereof. The reaction also preferably is conducted in the presence of a base, such as dimethylaminopyridine, diisopropylethylamine, pyridine, triethylamine, etc. to neutralize any acids generated and at a temperature from 0° C. up to about 22° C. (room temperature).
- 2. Second Method
- Turning now to the second method illustrated in FIGS. 2a and 2 b, an alternative synthetic technique is shown using the same moieties for J and B4 as that which was used in the first method. In this embodiment, the protected intermediate (IX) is reacted with a B moiety, e.g. Drug-OH as shown or Drug-NH2, prior to being deprotected. This results in the formation of a linkable ester-containing moiety (XI) which is then subjected to deprotecting to give (XIa) and polymer conjugating steps described above in the first method A to form the polymer transport form (IXd). FIG. 2a shows the formation of symmetrical terminally branched conjugates while FIG. 2b shows the formation of asymmetrical terminally branched conjugates. Amine-containing prodrugs can be made in the same way.
-
-
- wherein (x) represents the degree of polymerization and “Drug” represents a residue of a hydroxyl- or amine-containing biologically active compound which has undergone a substitution reaction which results in the attachment of the biologically active moiety to the branched polymer.
- Another aspect of the present invention provides methods of treatment for various medical conditions in mammals. The methods include administering to the mammal in need of such treatment, an effective amount of a prodrug, such as a camptothecin-20-PEG ester, which has been prepared as described herein. The compositions are useful for, among other things, treating neoplastic disease, reducing tumor burden, preventing metastasis of neoplasms and preventing recurrences of tumor/neoplastic growths in mammals.
- The amount of the prodrug administered will depend upon the parent molecule included therein. Generally, the amount of prodrug used in the treatment methods is that amount which effectively achieves the, desired therapeutic result in mammals. Naturally, the dosages of the various prodrug compounds will vary somewhat depending upon the parent compound, rate of in vivo hydrolysis, molecular weight of the polymer, etc. In general, however, prodrug taxanes are administered in amounts ranging from about 5 to about 500 mg/m2 per day, based on the amount of the taxane moiety. Camptothecin prodrugs are also administered in amounts ranging from about 5 to about 500 mg/m2 per day. The range set forth above is illustrative and those skilled in the art will determine the optimal dosing of the prodrug selected based on clinical experience and the treatment indication. Actual dosages will be apparent to the artisan without undue experimentation.
- The prodrugs of the present invention can be included in one or more suitable pharmaceutical compositions for administration to mammals. The pharmaceutical compositions may be in the form of a solution, suspension, tablet, capsule or the like, prepared according to methods well known in the art. It is also contemplated that administration of such compositions may be by the oral and/or parenteral routes depending upon the needs of the artisan. A solution and/or, suspension of the composition may be utilized, for example, as a carrier vehicle for injection or infiltration of the composition by any art known methods, e.g., by intravenous, intramuscular, subdermal injection and the like.
- Such administration may also be by infusion into a body space or cavity, as well as by inhalation and/or intranasal routes. In preferred aspects of the invention, however, the prodrugs are parenterally administered to mammals in need thereof
- The following examples serve to provide further appreciation of the invention but are not meant in any way to restrict the effective scope of the invention. The underlined and bold-faced numbers recited in the Examples correspond to those shown in the Figures.
- A mixture of iminodiacetic acid (1, 2 g, 15.03 mmol), di-t-butyl dicarbonate (3.9 g, 18.0 mmol), and sodium hydroxide (0.721 g, 18.0 mmol) in water (50 mL) was stirred at room temperature for 18 hours. The reaction solution was washed with 20 mL of methylene chloride (CH2Cl2) followed by adjusting pH to 2.5 with 6 N HCl. The resulting mixture was extracted with ethyl acetate (2×300 mL) and the combined organic layer was dried over anhydrous magnesium sulfate (MgSO4). The solvent was removed in vacuo to give 1.0 g (29%) of 2.
-
- A mixture of 2 (200 mg, 0.86 mmol) and camptothecin (3, 717 mg, 2.2 mmol) in anhydrous CH2Cl2 (50 mL) was cooled in an ice bath for 30 minutes before adding 1,3-diisopropylcarbodiimide (DIPC, 324 mg, 2.4 mmol) and 4-dimethylaminopyridine (DMAP, 272 mg, 2.2 mmol). The reaction mixture was left in the ice bath overnight and was allowed to warm to room temperature slowly. The solution was filtered and washed with water (20 mL) and 1N HCl (20mL). The organic layer was dried over anhydrous MgSO4 and concentrated. The residue was purified by silica gel column chromatography (2.5% methanol in CH2Cl2) to give 432 mg (56%) of 4.
-
- A solution of 4 (300 mg, 0.34 mmol) in anhydrous CH2Cl2 (5 mL) and trifluoroacetic acid (TFA, 2.5 mL) was stirred at room temperature for 3 hours. The reaction mixture was concentrated and the solid was recrystallized from ethyl ether to give 258 mg (78%) of 5 as a TFA salt.
-
- PEG (40 kDa) dicarboxylic acid (6, 2.0 g, 0.05 mmol) was azeotroped for 2 hours in toluene, followed by removal of the solvent in vacuo. Anhydrous-CH2Cl2 (20 mL) was added to the residue followed by the addition of 5 (0.16 g, 0.20 mmol), DIPC (25 mg, 0.20 mmol), and DMAP (25 mg, 0.20 mmol). The reaction mixture was stirred at room temperature overnight followed by removal of the solvent in vacuo. The residue was recrystallized from 2-propanol to yield 0.8 g (69%) of 7 as a white solid.
- 13C NMR (67.80 MHz, CDCl3) δ 7.25, 31.43, 49.35, 49.64, 66.80, 68.66, 71.16 (PEG), 76.06, 95.57, 119.96, 127.71, 127.89, 128.13, 129.38, 130.34, 130.89, 145.11, 146.09, 148.54, 151.93, 156.94, 166.89, 170.58.
- PEG (40 kDa) dithiazolidine thione (8, 1 g, 0.025 mmol) is added to the mixture of 1 (14 mg, 0.11 mmol) and N,N-diisopropylethylamine (DIPEA, 37 μL, 0.20 mmol) in anhydrous CH2Cl2 (15 mL). The mixture is stirred at room temperature overnight. The solvent is removed under reduced pressure and the residue is recrystallized from 2-propanol to give 9.
- DIPC (13 mg, 0.10 mmol) is added to the mixture of 9 (1.0 g, 0.025 mmol), DMAP (13 mg, 0.10 mmol), and 3 (35 mg, 0.1 mmol) in anhydrous CH2Cl2 (20 mL). The solution is stirred at room temperature overnight followed by removal of the solvent in vacuo. The residue is recrystallized from 2-propanol (80 mL) to give 7.
- A solution of di-t-butyl dicarbonate (26.46 g, 0.12 mol) in chloroform (50 mL) was added to the solution of diethanolamine (10, 12.63 g, 0.12 mol) in chloroform (50 mL) slowly at room temperature. The reaction solution was stirred at room temperature for 1 hour, followed by washing with water (30 mL) and the organic layer was dried over anhydrous MgSO4. The solvent was removed under reduced pressure to give 11 (20 g, 83%).
-
- Compound 11 (9.5 g, 46.34 mmol) was dissolved in anhydrous toluene (200 mL) by warming and the solution cooled to −20° C. followed by the addition of potassium t-butoxide (1 M solution in t-butanol, 70 mL, −70 mmol). The mixture was stirred at −20° C. for 5 hours and then cooled to −30° C. Ethyl bromoacetate (30.96 g, 185.35 mmol) was added to the solution and the reaction mixture was stirred at −15° C. for 3 hours. The solution was washed with water (50 mL) and the organic layer was dried over anhydrous MgSO4. The solvent was removed in vacuo to give a crude product which was purified by silica gel column chromatography (ethyl acetate/hexane=1.1, v/v) to give 8.2 g (48%) of 12.
-
- A solution of NaOH (10 g, 250 mmol) in water (10 mL) and ethanol (100 mL) was added to a solution of 12 (8.0 g, 21.22 mmol) in ethanol (80 mL). The reaction solution was stirred at room temperature for 1.5 hours and cooled to 0° C. The pH was adjusted to 2.5 with 6N HCl. The mixture was filtered and the filtrate was concentrated in vacuo. Chloroform (300 mL) was added to the residue and washed with water (3×50 mL). The organic layer was dried over anhydrous MgSO4 and concentrated under reduced pressure to give 5.0 g (73%) of 13.
-
- A mixture of 13 (2 g, 6.23 mmol), 3 (5.643 g, 16.20 mmol), DMAP (1.979 g, 16.20 mmol), and DIPC (2.041 g, 16.20 mmol) in anhydrous CH2Cl2 (50 mL) was stirred at room temperature for 20 hours. The reaction mixture was filtered and the filtrate washed with water (30 mL) and dried over anhydrous MgSO4. The solution was concentrated to give crude product which was purified by silica gel column chromatography (2.5% methanol in CH2Cl2) to give 14 as a light yellow solid (2.45 g, 40%).
-
δ 5 0.96 (t, 6H, J=8.1 Hz), 1.38 (s, 9H), 2.20 (qd, 4H, J=13.5, 8.1 Hz), 3.47 (bs, 4H), 3.63 (bs, 4H), 4.25 (s, 4H), 5.24 (s, 4H) 5.39 (d, 2H, J=13.5 Hz), 5.66 (d, 2H, J=13.5 Hz), 7.19 (s, 2H), 7.65 (t, 2H, J=6.8 Hz), 7.80 (t, 2H, J=6.8 Hz), 7.93 (d, 2H, J=8.1 Hz), 8.2 (d, 2H, J=8.1 Hz), 8.36 (s, 2H). 13C NMR (67.80 MHz, CDCl3) δ 7.46, 28.27, 31.70, 47.53, 47.74, 49.83, 67.06, 67.84, 70.37, 76.22, 790.68, 95.76, 120.19, 127.92, 128.07, 128.36, 129.53, 130.55, 131.07, 145.29, 146.30, 148.71, 152.15, 155.25, 157.18, 167.09, 169.36. - Compound 14 (0.74 g, 0.75 mmol) was dissolved in CH2CH2 (10 mL) and TFA (5 mL). The reaction solution was stirred at room temperature for 2 hours and concentrated under reduced pressure. The residue was recrystallized from CH2Cl2-ethyl ether to give 0.6 g (100%) of 15 as a TFA salt.
-
- A mixture of 15 (79,8 mg, 0,09 mmol), di-SC-PEG (40 kDa, 1.0 g, 0.025 mmol), and DMAP (11.1 mg, 0.09 mmol) in anhydrous chloroform (20 mL) was stirred at room temperature overnight. The solvent was removed in vacuo and the residue was recrystallized from 2-propanol (80 mL) to give 0.92 g (92%) of 16.
-
- Compound 6 (3 g, 0.075 mmol) was azeotroped for 2 hours in 90 mL of toluene. The solvent was removed in vacuo and the residue was dissolved in 50 mL of anhydrous CH2Cl2. Compound 15 (263.5 mg, 0.3 mmol), DMAP (45.7 mg, 0.38 mmol), and DIPC (37.7 mg, 0.30 mmol) were added to the solution and the reaction mixture was stirred at room temperature overnight. The reaction solution was diluted with 100 mL of CH2Cl2 and washed with 1N HCl (2×20 mL) and water (20 mL). The organic layer was dried over anhydrous MgSO4 and the solvent was removed under reduced pressure. The residue was recrystallized from 2-propanol (100 mL) to give 2.44 g (80%) of 17.
-
- mPEG (20 kDa) thiazolidine thione (19, 4 g, 0.2 mmol) was added to a solution of tris(hydroxymethyl)aminomethane (TRIS, 18, 2.4 g, 20 mmol) in water (60 mL). The mixture was stirred at room temperature overnight, followed by extraction with CH2Cl2 (2×50 mL). The combined organic layer was washed with brine (60 mL) and dried over anhydrous MgSO4. The solvent was removed under reduced pressure and the residue was recrystallized from 2-propanol to give 2.0 g (50%) of 20.
-
- A solution of 20 (10 g, 2 mmol) in 100 mL of toluene is azeotroped for 2 hours and is cooled to 35° C. followed by the addition of 10.5 mL (10.5 mmol) of 1.0 M potassium f-butoxide in t-butanol. The mixture is stirred for 1 hour at 35° C. followed by the addition of 3.9 g (20 mmol) of t-butyl bromoacetate. The reaction mixture is stirred at 40° C. overnight, filtered through celite and solvent removed in vacuo. The residue is recrystallized from chilled CH2Cl2-ethyl ether to yield ester of 20. The ester is dissolved in CH2Cl2 (100 mL) and TFA (50 mL). The reaction solution is stirred at room temperature for 2 hours and concentrated under reduced pressure. The residue is recrystallized from CH2Cl2-ethyl ether to give 21.
- Compound 21 (3 g, 0.56 mmol) is azeotroped for 2 hours in 90 mL of toluene. The solvent is removed in vacuo and the residue is dissolved in 60 mL of anhydrous CH2Cl2. Compound 3 (1.17 g, 3.4 mmol), DMAP (829.6 mg, 6.8 mmol), and DIPC (1.37 g, 13.6 mmol) are added to the solution and the reaction mixture is stirred at room temperature overnight. The reaction solution is diluted with 100 mL of CH2Cl2 and washed with IN HCl (2×20 mL) and water (20 mL). The organic layer is dried over anhydrous MgSO4 and the solvent is removed under reduced pressure. The residue is recrystallized from 2-propanol (300 mL) to give 22.
- DIPC (0.72 g, 5.8, mmol) was added to a solution of N-t-Boc-L-aspartic acid (23, 1.34 g, 5.8 mmol), 3 (2.0 g, 5.8 mmol), DMAP (0.7 g, 5.8 mmol), and in anhydrous CH2Cl2 (25 mL) at 0° C. The mixture was allowed to warm to room temperature overnight, followed by washing with 1% aqueous sodium bicarbonate (4×15 mL) and 0.1 N HCl (2×15 mL). The organic layer was dried-over anhydrous MgSO4. The solution was concentrated to give a crude product as a solid which was recrystallized in methanol to give 24 (2.1 g, 40%).
-
- A solution of 24 (500 mg, 0.56 mmol) in anhydrous CH2Cl2 (5 mL) and trifluoroacetic acid (TFA, 2.5 mL) was stirred at room temperature for 1 hour, followed by addition of ethyl ether (40 mL). The solid was filtered and washed with ethyl ether to give 25 (0.4 g, 75%).
- PEG (40 kDa) dicarboxylic acid (6, 1.0 g, 0.025 mmol) was azeotroped for 2 h in toluene, followed by removal of the solvent in vacuo. Anhydrous CH2Cl2 (20 mL) was added to the residue followed by the addition of 25 (94 mg 0.10 mmol), DIPC (13 mg, 0.10 mmol), and DMAP (25 mg, 0.20 mmol). The reaction mixture was stirred at room temperature overnight followed by removal of the solyent in vacuo. The residue was recrystallized from 2-propanol to yield 0.81 g (81%) of 7 as a white solid.
- A mixture of 6 (5 g 0.125 mmol), L-aspartic acid dimethylester HCl (27, 98.5 mg, 0.50 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC, 191 mg, 1.0 mmol), and DMAP (122 mg, 1.0 mmol) in anhydrous CH2Cl2 (80 mL) was stirred at room temperature overnight. The solvent was removed and the residue was recrystallized from 2-propanol to give 4.2 g (84%) of 28.
-
- Compound 28 (3.8 g, 0.094 mmol) and lithium hydroxide (24 mg, 0.57 mmol) were stirred in water (20 mL) for 6 hours, followed by acidification with 1N HCl to adjust the pH to 3. The product was extracted to CH2Cl2 and recrystallized with chilled CH2Cl2-ether to give 3.5 g (92%) of 29.
-
- A mixture of 29 (1.0 g, 0.025 mmol), paclitaxel (30, 170 mg, 0.20 mmol), EDC (76 mg, 0.4 mmol), and DMAP (76 mg, 0.6 mmol) in anhydrous CH2Cl2(20 mL) was stirred at room temperature for 16 hours. The mixture was concentrated in vacuo and the residue was recrystallized from 2-propanol to give 0.95 g (95%) of 31.
-
- A mixture of t-Boc-β-Alanine (32, 200 mg, 1.06 mmol), 2-mercapto-thiazdlidine (33, 252 mg, 2.12 mmol), EDC (407 mg, 2.12 mmol), and DMAP (516 mg, 4.23 mmol) in anhydrous CH2Cl2 (10 mL) is stirred at room temperature overnight. The reaction mixture is diluted with 40 mL of CH2Cl2 and washed twice with 1% NaHCO3 (25 mL) and twice with IN HCl. The organic layer is dined over anhydrous sodium sulfate and the solvent is removed in vacuo to give 34.
- A mixture of 34 (1.79 g, 6.17 mmol) and 35 (4.5 g, 18.5 mmol) in anhydrous pyridine (125 mL) is stirred at 40° C. overnight. The reaction mixture is concentrated in vacuo and the residue is purified by column chromatography to give 36.
- Compound 36 (1 g) is dissolved in TFA (10 mL) and CH2Cl2(10 mL) and the solution stirred at room temperature for 2 hours. The solvent is removed in vacuo and the product precipitated by adding anhydrous ethyl ether to give 37 as the TFA salt.
- A mixture of 22 (1.0 g, 0.025 mmol), 37 (106 mg, 0.20 mmol), EDC (76 mg, 0.4 mmol), and DMAP (76 mg, 0.6 mmol) in anhydrous CH2Cl2 (20 mL) is stirred at room temperature for 16 hours. The mixture is concentrated in vacuo and the residue recrystallized from 2-propanol to give 38.
- In this example, a polymeric conjugate of gemcitabine is prepared by repeating the procedures of Examples 24-26 using gemcitabine in place of Ara-C (35).
-
PEG 40 kDa diamine hydrochloride (5 g, 0.125 mmol) is dissolved in anhydrous dichloromethane (50 mL) and EDC (95 mg, 0.49 mmol) and DMAP (95 mg, 0.78 mmol) are added. The solution is stirred for 3 hours at room temperature. The dianhydride of diethylenetriaminepentaacetic acid (DADTPA, 134 mg, 0.38 mmol) is added to this solution and the mixture stirred overnight at room temperature. The solvent is removed in vacuo and the residue recrystallized from dichloromethane/ethyl ether to give 40. - A mixture of 40 (1.0 g, 0.025 mmol), 30 (170 mg, 0.20 mmol), and DMAP (76 mg, 0.6 mmol) in anhydrous CH2Cl2(20 mL) is stirred at room temperature for 16 hours. The mixture is concentrated in vacuo and the residue is recrystallized from 2-propanol to give 41.
- The various publications, patents, patent applications and published applications mentioned in this application are hereby incorporated by reference herein.
- While there have been described what are presently believed to be the preferred embodiments of the invention, those skilled in the art will realize that changes and modifications may be made without departing from the spirit of the invention. It is intended to claim all such changes and modifications as fall within the true scope of the invention.
Claims (22)
1. A compound comprising the formula:
E1-4 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy, C1-6 heteroalkoxy,
and at least one E1-4 includes a B moiety, wherein B is a leaving group, OH, a residue of a hydroxyl-containing moiety, a residue of an amine-containing moiety or
wherein J1 is the same as J, or another member of the group defining J and E5 is the same as E1-4, or another member of the group defining E1-4;
Y1-2 are independently O, S or NR9,
M is a heteroatom selected from either X or Q; wherein X is an electron withdrawing group and Q is a moiety containing a free electron pair positioned three to six atoms from C(═Y2);
R2-5 and R7-9 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy;
(m1) and (m2) are independently zero or one;
(n1), (n2), (p1), (p2) and (q) are independently zero or a positive integer;
Z is an electron withdrawing group; and
R1 is a polymeric residue.
3. The compound of claim 1 , wherein Y1 and Y2 are oxygen.
4. The compound of claim 1 , wherein R2-5, R7 and R8 are hydrogen.
5. The compound of claim 1 , wherein X is selected from the group consisting of O, S, SO, SO2, C(Y3) and NR6, wherein Y3 is selected from the group consisting of O, S and R9, and R6 is selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls and substituted C1-6 heteroalkyls.
6. The compound of claim 1 , wherein Q is selected from the group consisting of C2-4 alkyls, cycloalkyls, aryls, aralkyl groups substituted with a member of the group consisting of NH, O, S, —CH2—C(O)—NH—, and ortho-substituted phenyls.
7. The compound of claim 1 , wherein (p1) and (p2) are 1.
8. The compound of claim 1 , wherein (n1) and (n2) are individually 1 or 2.
9. The compound of claim 8 , wherein (n1) is 1 and (n2) is 2.
10. The compound of claim 1 , wherein (m1) and (m2) are 1.
11. The compound of claim 1 , wherein (q) is 1.
12. The compound of claim 1 , wherein R1 comprises a polyalkylene oxide residue.
13. The compound of claim 12 , wherein said polyalkylene oxide residue comprises polyethylene glycol.
14. The compound of claim 1 wherein said polymeric residue has a molecular weight of from about 2,000 to about 100,000.
15. The compound of claim 14 , wherein said polymeric residue has a molecular weight of from about 20,000 to about 40,000.
16. The compound of claim 1 wherein B is a residue of a member of the group consisting of Ara-C, camptothecin, camptothecin analogs, paclitaxel, taxoteres, gemcitabine, podophyllotoxin, fluconazole, ciclopirox, amphoteracin B, nystatin, doxorubicin, daunorubicin, maytansine, vancomycin and erythromycin.
17. The compound of claim 1 wherein B is a residue of a member of the group consisting of anti-tumor agents; cardiovascular agents, anti-neoplastics anti-infectives, anti-fungals, anti-anxiety agents, gastrointestinal agents, central nervous system-activating agents, analgesics, fertility or contraceptive agents, anti-inflammatory agents, steroidal agents, anti-urecemic agents, cardiovascular agents, vasodilating agents and vasoconstricting agents.
19. A compound of claim 1 , having a formula selected from the group consisting of:
wherein (x) represents the degree of polymerization and “Drug” represents a residue of a hydroxyl- or amine-containing biologically active compound which has undergone a substitution reaction which results in the attachment of the biologically active moiety to the branched polymer.
20. A method of preparing a polymeric transport system, comprising
a) reacting a compound of formula:
E1-4 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy, C1-6 heteroalkoxy,
and at least one of E1-4 includes a B moiety, wherein B is a leaving group, OH or
wherein J1 is the same as J, or another member of the group defining J and E5 is the same as E1-4 or another member of the group defining E1-4;
Y1 is O, S, or NR9;
R4-5 and R7-9 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-5 heteroalkyls, substituted C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy, and C1-6 heteroalkoxy;
(m1) and (m2) are independently zero or one;
(n1), (n2), (p1), and (p2) are independently zero or a positive integer; and
(Z) is an electron withdrawing group;
with a compound of the formula:
wherein
B2 is a leaving group which is capable of reacting with an unprotected amine;
Y2 is O, S, or NR9;
q is independently zero or a positive integer;
R2-3 are selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy, and C1-6 heteroalkoxy,
M is a heteroatom selected from either X or Q; wherein X is an electron withdrawing group and Q is a moiety containing a free electron pair positioned three to six atoms from C(═Y2); and
(R1) is a polymeric residue; and
b) reacting the resultant compound with a sufficient amount of a biologically active moiety having a substitutable hydroxyl or amino group.
21. A method of preparing a polymeric transport systems comprising
a) reacting a sufficient amount of a biologically active moiety having a substitutable hydroxyl or amino group with a compound of the formula:
wherein B3 is a cleavable protecting group;
E1-4 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy, C1-6 heteroalkoxy,
and at least one of E1-4 includes a B moiety, wherein B is a leaving group, OH, or
wherein J1 is the same as J, or another member of the group defining J and E5 is the same as E1-4 or another member of the group defining E1-4;
Y1 is O, S, or NR9;
R4-5 and R7-9 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls; substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy, and C1-6 heteroalkoxy;
(m1) and (m2) are independently zero or one;
(n1), (n2), (p1), and (p2) are independently zero or a positive integer; and
(Z) is an electron withdrawing group;
with a biologically active moiety having a hydroxyl or amine group;
b) deprotecting the resultant intermediate by removing B3; and
c) reacting the deprotected intermediate compound with a compound of the formula
wherein
B2 is a leaving group which is capable of reacting with an unprotected amine;
Y2 is O, S, or NR9;
q is independently zero or a positive integer;
R2-3 are selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy, and C1-6 heteroalkoxy;
M is a heteroatom selected from either X or Q; wherein X is an electron withdrawing group and Q is a moiety containing a free electron pair positioned three to six atoms from C(═Y2); and
(R1) is a polymeric residue.
22. A method of treating a mammal with prodrugs, comprising:
administering to a mammal in need of such treatment an effective amount of a composition of claim 1 where in B is a residue of a biologically active moiety.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/638,031 US20040053976A1 (en) | 1998-04-17 | 2003-08-08 | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/062,305 US6153655A (en) | 1998-04-17 | 1998-04-17 | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US09/293,624 US6395266B1 (en) | 1998-04-17 | 1999-04-16 | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US10/067,930 US6638499B2 (en) | 1998-04-17 | 2002-02-06 | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US10/638,031 US20040053976A1 (en) | 1998-04-17 | 2003-08-08 | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/067,930 Continuation US6638499B2 (en) | 1998-04-17 | 2002-02-06 | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040053976A1 true US20040053976A1 (en) | 2004-03-18 |
Family
ID=22041624
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/062,305 Expired - Lifetime US6153655A (en) | 1998-04-17 | 1998-04-17 | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US09/293,624 Expired - Fee Related US6395266B1 (en) | 1998-04-17 | 1999-04-16 | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US10/067,930 Expired - Fee Related US6638499B2 (en) | 1998-04-17 | 2002-02-06 | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US10/638,031 Abandoned US20040053976A1 (en) | 1998-04-17 | 2003-08-08 | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/062,305 Expired - Lifetime US6153655A (en) | 1998-04-17 | 1998-04-17 | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US09/293,624 Expired - Fee Related US6395266B1 (en) | 1998-04-17 | 1999-04-16 | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US10/067,930 Expired - Fee Related US6638499B2 (en) | 1998-04-17 | 2002-02-06 | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
Country Status (6)
Country | Link |
---|---|
US (4) | US6153655A (en) |
EP (1) | EP1071455A4 (en) |
JP (1) | JP4860813B2 (en) |
AU (1) | AU3648399A (en) |
CA (1) | CA2328922C (en) |
WO (1) | WO1999053951A1 (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006136586A2 (en) * | 2005-06-22 | 2006-12-28 | Complex Biosystems Gmbh | N, n-bis- (2-hydroxyethyl) glycine amide as linker in polymer conjugated prodrugs |
WO2007081596A3 (en) * | 2006-01-10 | 2007-12-13 | Enzon Pharmaceuticals Inc | High efficiency method of preparing polyalkylene oxide carboxylic acids |
WO2012098557A1 (en) * | 2011-01-20 | 2012-07-26 | Institute Of Life Sciences | Pegylated gemcitabine derivative and process for preparing the same |
WO2017112826A3 (en) * | 2015-12-21 | 2017-08-31 | Duke University | Polymer conjugates having reduced antigenicity and methods of using the same |
US10364451B2 (en) | 2013-05-30 | 2019-07-30 | Duke University | Polymer conjugates having reduced antigenicity and methods of using the same |
US10385115B2 (en) | 2015-03-26 | 2019-08-20 | Duke University | Fibronectin type III domain-based fusion proteins |
US10392611B2 (en) | 2013-05-30 | 2019-08-27 | Duke University | Polymer conjugates having reduced antigenicity and methods of using the same |
US11103593B2 (en) | 2013-10-15 | 2021-08-31 | Seagen Inc. | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
US11135301B2 (en) | 2016-09-14 | 2021-10-05 | Duke University | Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs |
US11155584B2 (en) | 2016-09-23 | 2021-10-26 | Duke University | Unstructured non-repetitive polypeptides having LCST behavior |
US11229708B2 (en) | 2015-12-04 | 2022-01-25 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
US11458205B2 (en) | 2015-08-04 | 2022-10-04 | Duke University | Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same |
US11467156B2 (en) | 2016-06-01 | 2022-10-11 | Duke University | Nonfouling biosensors |
US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
US11554097B2 (en) | 2017-05-15 | 2023-01-17 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
US11649275B2 (en) | 2018-08-02 | 2023-05-16 | Duke University | Dual agonist fusion proteins |
US11648200B2 (en) | 2017-01-12 | 2023-05-16 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
US11680083B2 (en) | 2017-06-30 | 2023-06-20 | Duke University | Order and disorder as a design principle for stimuli-responsive biopolymer networks |
US11730822B2 (en) | 2017-03-24 | 2023-08-22 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
US11844839B2 (en) | 2016-03-25 | 2023-12-19 | Seagen Inc. | Process for the preparation of pegylated drug-linkers and intermediates thereof |
Families Citing this family (158)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100361933B1 (en) * | 1993-09-08 | 2003-02-14 | 라 졸라 파마슈티칼 컴파니 | Chemically defined nonpolymeric bonds form the platform molecule and its conjugate |
US6624142B2 (en) * | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
DE69939033D1 (en) * | 1998-03-12 | 2008-08-14 | Nektar Therapeutics Al Corp | Process for the preparation of polymer conjugates |
US6153655A (en) * | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US6458953B1 (en) * | 1998-12-09 | 2002-10-01 | La Jolla Pharmaceutical Company | Valency platform molecules comprising carbamate linkages |
KR100549108B1 (en) * | 1999-02-05 | 2006-02-06 | 삼성토탈 주식회사 | A method for removing the paint piece from polypropylene bumper coverd with paint |
EP1183230A1 (en) * | 1999-06-08 | 2002-03-06 | La Jolla Pharmaceutical | Valency platform molecules comprising aminooxy groups |
US6713454B1 (en) * | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
US6777387B2 (en) * | 2000-03-31 | 2004-08-17 | Enzon Pharmaceuticals, Inc. | Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same |
CA2414076A1 (en) | 2000-06-08 | 2001-12-13 | La Jolla Pharmaceutical Company | Multivalent platform molecules comprising high molecular weight polyethylene oxide |
DE10048417A1 (en) * | 2000-09-29 | 2002-04-11 | Roche Diagnostics Gmbh | Branched linker connections |
US6350756B1 (en) | 2001-01-18 | 2002-02-26 | California Pacific Medical Center | Camptothecin derivatives |
MXPA03007392A (en) * | 2001-02-20 | 2003-12-04 | Enzon Inc | Terminally-branched polymeric linkers and polymeric conjugates containing the same. |
DK1361895T3 (en) * | 2001-02-20 | 2008-02-18 | Enzon Inc | End group branched polymeric linkers and polymeric conjugates containing these |
US6855720B2 (en) | 2001-03-01 | 2005-02-15 | California Pacific Medical Center | Nitrogen-based camptothecin derivatives |
US6403604B1 (en) | 2001-03-01 | 2002-06-11 | California Pacific Medical Center | Nitrogen-based camptothecin derivatives |
DE10209821A1 (en) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Coupling of proteins to a modified polysaccharide |
DE10209822A1 (en) * | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Coupling of low molecular weight substances to a modified polysaccharide |
ATE368066T1 (en) * | 2002-03-13 | 2007-08-15 | Beijing Jiankai Technology Co | HYDROPHILIC POLYMER DERIVATIVE WITH Y-BRANCH AND PRODUCTION PROCESS THEREOF; MEDICAL COMPOSITE CONTAINING THE ABOVE COMPOUND |
JP4527404B2 (en) * | 2002-04-04 | 2010-08-18 | エンゾン,インコーポレーテッド | Polymeric acyl derivatives of indole |
AU2003243397A1 (en) * | 2002-06-03 | 2003-12-19 | California Pacific Medical Center | Homo-camptothecin derivatives |
WO2003101998A1 (en) * | 2002-06-03 | 2003-12-11 | California Pacific Medical Center | Nitrogen-based homo-camptothecin derivatives |
US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
RU2329274C2 (en) * | 2002-09-11 | 2008-07-20 | Фрезениус Каби Дойчланд Гмбх | Method of obtaining derivatives of hydroxyalkyl starch |
AU2003280592B2 (en) | 2002-10-31 | 2008-12-18 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight derivatives of camptothecins |
US7273845B2 (en) * | 2002-11-12 | 2007-09-25 | Enzon Pharmaceuticals, Inc. | Polymeric prodrugs of vancomycin |
WO2004044223A2 (en) * | 2002-11-12 | 2004-05-27 | Enzon Pharmaceuticals, Inc. | Prodrugs of vancomycin with hydrolysis resistant polymer linkers |
US7670627B2 (en) * | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
US8034900B2 (en) | 2002-12-30 | 2011-10-11 | Amylin Pharmaceuticals, Inc. | Water-soluble thioester and selenoester compounds and methods for making and using the same |
US7208145B2 (en) * | 2002-12-31 | 2007-04-24 | Nektar Therapeutics Al, Corporation | Polymeric reagents comprising a ketone or a related functional group |
CA2528383A1 (en) * | 2003-06-05 | 2005-01-27 | University Of Maryland, Baltimore County | Inactivators and bivalent inhibitors of glyoxalase i and methods of inhibiting tumor growth |
GB0316294D0 (en) * | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
WO2005014655A2 (en) * | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
US20080274948A1 (en) * | 2003-08-08 | 2008-11-06 | Fresenius Kabi Deutschland Gmbh | Conjugates of Hydroxyalkyl Starch and G-Csf |
EP2626083A1 (en) * | 2003-09-17 | 2013-08-14 | Nektar Therapeutics | Multi-arm polymer prodrugs |
US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
WO2005030835A1 (en) * | 2003-09-25 | 2005-04-07 | Terumo Kabushiki Kaisha | Polyethylene glycol derivatives and drug carriers containing the same as the membrane constituent |
EP1725589A1 (en) * | 2004-03-11 | 2006-11-29 | Fresenius Kabi Deutschland GmbH | Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination |
EP2279752A3 (en) * | 2004-03-11 | 2011-08-24 | Fresenius Kabi Deutschland GmbH | Conjugates of hydroxyalkyl starch and a protein, prepared by native chemical ligation |
MX2007000883A (en) * | 2004-07-19 | 2007-04-02 | Biocon Ltd | Insulin-oligomer conjugates, formulations and uses thereof. |
ES2410591T3 (en) | 2004-09-22 | 2013-07-02 | Nippon Kayaku Kabushiki Kaisha | New block copolymer, micellar preparation and antineoplastic agent containing it as active ingredient |
CA2598528A1 (en) * | 2005-03-11 | 2006-09-14 | Fresenius Kabi Deutschland Gmbh | Production of bioactive glycoproteins from inactive starting material |
EP1868652A2 (en) | 2005-04-05 | 2007-12-26 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Method for shielding functional sites or epitopes on proteins |
DE102005041570A1 (en) * | 2005-09-01 | 2007-03-22 | Celares Gmbh | Highly branched reagents for modifaction of biopharmaceuticals, their preparation and use |
US7875602B2 (en) * | 2005-10-21 | 2011-01-25 | Sutter West Bay Hospitals | Camptothecin derivatives as chemoradiosensitizing agents |
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
WO2007073486A2 (en) * | 2005-12-20 | 2007-06-28 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
US7709227B2 (en) * | 2006-01-04 | 2010-05-04 | Phasebio Pharmaceuticals, Inc. | Multimeric ELP fusion constructs |
US8133707B2 (en) | 2006-01-17 | 2012-03-13 | Enzon Pharmaceuticals, Inc. | Methods of preparing activated polymers having alpha nitrogen groups |
US7671067B2 (en) * | 2006-02-09 | 2010-03-02 | Enzon Pharmaceuticals, Inc. | Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin |
US7462627B2 (en) * | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
US20100166700A1 (en) * | 2006-02-28 | 2010-07-01 | Oligasis Corporation | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates and Their Preparation |
KR20080106254A (en) | 2006-03-28 | 2008-12-04 | 니폰 가야꾸 가부시끼가이샤 | Polymer conjugate of taxane |
AU2007252678A1 (en) | 2006-05-18 | 2007-11-29 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of podophyllotoxin |
WO2007146835A2 (en) * | 2006-06-09 | 2007-12-21 | Enzon Pharmaceuticals, Inc. | Indenoisoquinoline-releasable polymer conjugates |
AU2007274402A1 (en) * | 2006-07-19 | 2008-01-24 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of combretastatin |
BRPI0716808A2 (en) * | 2006-09-15 | 2013-11-05 | Enzon Pharmaceuticals Inc | Lysine-Based Polymeric Binders |
US8367065B2 (en) * | 2006-09-15 | 2013-02-05 | Enzon Pharmaceuticals, Inc. | Targeted polymeric prodrugs containing multifunctional linkers |
WO2008034124A2 (en) * | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Targeted polymeric prodrugs containing multifunctional linkers |
US7985783B2 (en) | 2006-09-21 | 2011-07-26 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
WO2008041610A1 (en) * | 2006-10-03 | 2008-04-10 | Nippon Kayaku Kabushiki Kaisha | Compound of resorcinol derivative with polymer |
US8334364B2 (en) | 2006-11-06 | 2012-12-18 | Nipon Kayaku Kabushiki Kaisha | High-molecular weight derivative of nucleic acid antimetabolite |
WO2008056654A1 (en) | 2006-11-08 | 2008-05-15 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of nucleic acid metabolic antagonist |
CA2669541C (en) * | 2006-11-30 | 2014-11-18 | Nektar Therapeutics Al, Corporation | Method for preparing a polymer conjugate |
CA2671209A1 (en) * | 2006-12-29 | 2008-07-10 | Enzon Pharmaceuticals, Inc. | Use of adenosine deaminase for treating pulmonary disease |
EP2125014A2 (en) * | 2007-01-16 | 2009-12-02 | Enzon Pharmaceuticals, Inc. | Posaconazole polymer conjugates and methods of treatment using posaconazole and polymer conjugates thereof |
AU2008213576B2 (en) * | 2007-02-09 | 2013-01-17 | Enzon Pharmaceuticals, Inc. | Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
ES2569940T3 (en) * | 2007-04-20 | 2016-05-13 | Sigma-Tau Rare Disease Ltd | Stable recombinant adenosine deaminase |
TWI486169B (en) * | 2007-04-20 | 2015-06-01 | Sigma Tau Rare Diseases S A | Enzymatic anticancer therapy |
US20090016985A1 (en) * | 2007-07-11 | 2009-01-15 | Enzon Pharmaceuticals, Inc. | Polymeric drug delivery system containing a multi-substituted aromatic moiety |
US20100203066A1 (en) * | 2007-08-20 | 2010-08-12 | Enzon Pharmaceuticals, Inc. | Polymeric linkers containing pyridyl disulfide moieties |
EP2206502B1 (en) * | 2007-09-28 | 2018-09-12 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of steroid |
EP2070950A1 (en) * | 2007-12-14 | 2009-06-17 | Fresenius Kabi Deutschland GmbH | Hydroxyalkyl starch derivatives and process for their preparation |
EP2070951A1 (en) * | 2007-12-14 | 2009-06-17 | Fresenius Kabi Deutschland GmbH | Method for producing a hydroxyalkyl starch derivatives with two linkers |
EP2258397B1 (en) * | 2008-03-18 | 2017-10-11 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of physiologically active substance |
PT2281006T (en) | 2008-04-30 | 2017-12-06 | Immunogen Inc | Cross-linkers and their uses |
WO2009136572A1 (en) | 2008-05-08 | 2009-11-12 | 日本化薬株式会社 | Polymer conjugate of folic acid or folic acid derivative |
EP2926825A1 (en) | 2008-06-27 | 2015-10-07 | Duke University | Therapeutic agents comprising elastin-like peptides |
CA2732508C (en) | 2008-08-11 | 2016-03-15 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
TW201010732A (en) * | 2008-08-29 | 2010-03-16 | Enzon Pharmaceuticals Inc | Method of treating RAS associated cancer |
AU2009297091B2 (en) | 2008-09-23 | 2015-03-05 | Nektar Therapeutics | Compositions and methods for achieving sustained therapeutic drug concentrations in a subject |
BRPI0920655A2 (en) * | 2008-10-07 | 2019-07-09 | Rexahn Pharmaceuticals Inc | conjugates and hpma-docetaxel or gemcitabine and their uses |
CN102215688A (en) * | 2008-10-21 | 2011-10-12 | 安龙制药公司 | Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
MX2011012044A (en) | 2009-05-13 | 2011-12-14 | Nektar Therapeutics | Oligomer-containing substituted aromatic triazine compounds. |
WO2010131675A1 (en) | 2009-05-15 | 2010-11-18 | 日本化薬株式会社 | Polymer conjugate of bioactive substance having hydroxy group |
IT1399351B1 (en) | 2009-06-16 | 2013-04-16 | Fidia Farmaceutici | PROCEDURE FOR THE SYNTHESIS OF GLYCOSAMINOGLICAN CONJUGATES (GAG) WITH BIOLOGICALLY ACTIVE MOLECULES, POLYMERIC CONJUGATES AND RELATIVE USES |
CN102481364A (en) * | 2009-07-22 | 2012-05-30 | 安龙制药公司 | Methods of treating her2 positive cancer with her2 receptor antagonist in combination with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
KR101887009B1 (en) | 2009-08-14 | 2018-08-09 | 파세비오 파마수티컬스 인코포레이티드 | Modified Vasoactive Intestinal Peptide |
WO2011025875A1 (en) * | 2009-08-27 | 2011-03-03 | Seachaid Pharmaceuticals, Inc. | Echinocandin derivatives |
EP2488207A4 (en) | 2009-10-13 | 2015-06-10 | Rexahn Pharmaceuticals Inc | Polymeric systems for the delivery of anticancer agents |
WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
US8816099B2 (en) | 2010-03-31 | 2014-08-26 | Nof Corporation | Polyfunctional polyoxyalkylene compound, and producing method and intermediate thereof |
WO2012004007A1 (en) | 2010-07-09 | 2012-01-12 | Fresenius Kabi Deutschland Gmbh | Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
US20130217871A1 (en) | 2010-07-09 | 2013-08-22 | Helmut Knoller | Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
AU2011276120B2 (en) | 2010-07-09 | 2013-12-19 | Azim Abul | Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
US20140073778A9 (en) | 2010-07-09 | 2014-03-13 | Fresenius Kabi Deutschland Gmbh | Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
CN102339813A (en) | 2010-07-14 | 2012-02-01 | 中国科学院微电子研究所 | Semiconductor structure and manufacturing method thereof |
EP2641605B1 (en) | 2010-11-17 | 2018-03-07 | Nippon Kayaku Kabushiki Kaisha | Polymer derivative of cytidine metabolism antagonist |
WO2012088445A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
WO2012088422A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
US9561262B2 (en) | 2011-06-06 | 2017-02-07 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
CA2840221A1 (en) | 2011-07-05 | 2013-01-10 | Bioasis Technologies Inc. | P97-antibody conjugates and methods of use |
US9034318B2 (en) | 2011-08-30 | 2015-05-19 | The Regents Of The University Of Colorado, A Body Corporate | Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria |
PT2754682T (en) | 2011-09-11 | 2017-08-29 | Nippon Kayaku Kk | Method for manufacturing block copolymer |
JP5945896B2 (en) | 2011-09-30 | 2016-07-05 | 日油株式会社 | Branched hetero polyfunctional polyoxyalkylene compounds and intermediates thereof |
CN103083680B (en) | 2011-11-07 | 2014-12-24 | 北京键凯科技有限公司 | Polyethylene glycol (PEG)-amino acid oligopeptide-irinotecan combo and its medicinal composition |
EP2797597B1 (en) | 2011-12-28 | 2020-02-26 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
CA3142817A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
CN103421175B (en) * | 2012-05-16 | 2015-09-09 | 中国石油化工股份有限公司 | N, N '-bis-fatty acyl hydroxyethyl aliphatic diamine polyethenoxy ether carboxylate or sulfonate and preparation method thereof |
WO2014022515A1 (en) | 2012-07-31 | 2014-02-06 | Bioasis Technologies, Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
CA2890190A1 (en) | 2012-11-12 | 2014-05-15 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
EP2920148B1 (en) | 2012-11-16 | 2019-06-12 | The Regents of the University of California | Pictet-spengler ligation for protein chemical modification |
US9675678B2 (en) | 2013-01-29 | 2017-06-13 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for treatment of homocystinuria |
WO2014160438A1 (en) | 2013-03-13 | 2014-10-02 | Bioasis Technologies Inc. | Fragments of p97 and uses thereof |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
AP2015008718A0 (en) | 2013-03-15 | 2015-09-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
EP2970196B1 (en) | 2013-03-15 | 2020-11-25 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
EP3919056A1 (en) | 2013-03-15 | 2021-12-08 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
EP3038657A2 (en) | 2013-08-28 | 2016-07-06 | Bioasis Technologies Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
PT3041513T (en) | 2013-09-08 | 2020-09-07 | Kodiak Sciences Inc | Factor viii zwitterionic polymer conjugates |
EA201992707A1 (en) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION |
CA3178867A1 (en) | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
KR20160098257A (en) | 2013-12-17 | 2016-08-18 | 노파르티스 아게 | Cytotoxic peptides and conjugates thereof |
EP3102208B1 (en) | 2014-02-07 | 2021-01-13 | Global Blood Therapeutics, Inc. | Crystalline polymorph of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
WO2015172046A1 (en) | 2014-05-08 | 2015-11-12 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating cystic fibrosis |
EA201692530A1 (en) | 2014-06-13 | 2017-07-31 | Новартис Аг | CYTOTOXIC PEPTIDES AND THEIR CONJUGATES |
WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
NZ746680A (en) | 2014-10-14 | 2020-07-31 | Halozyme Inc | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
US9938323B2 (en) | 2014-11-06 | 2018-04-10 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase |
JP6824888B2 (en) | 2015-02-09 | 2021-02-03 | フェーズバイオ ファーマシューティカルズ,インコーポレイテッド | Methods and compositions for treating muscle disorders and disorders |
MA41841A (en) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | ALDEHYDE COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, HYPOXIA, AND AUTOIMMUNE AND CONNECTIVE TISSUE DISEASES |
EP3310813A1 (en) | 2015-06-17 | 2018-04-25 | Novartis AG | Antibody drug conjugates |
NZ741552A (en) | 2015-11-09 | 2022-04-29 | Univ Colorado Regents | Compositions and methods for treatment of homocystinuria |
WO2017096230A1 (en) | 2015-12-04 | 2017-06-08 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
TWI752307B (en) | 2016-05-12 | 2022-01-11 | 美商全球血液治療公司 | Novel compound and method of preparing compound |
TW202332423A (en) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
KR102614466B1 (en) * | 2016-11-14 | 2023-12-14 | 비온디스 비.브이. | Method for preparing mono-protected alpha, omega-diamino alkanes |
US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
JP7146897B2 (en) | 2017-04-17 | 2022-10-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト | Optimization of enzyme replacement therapy for the treatment of homocystinuria |
CN111094462A (en) | 2017-12-26 | 2020-05-01 | 贝克顿·迪金森公司 | Deep ultraviolet excitable water-solvated polymer dyes |
JP2021519841A (en) | 2018-03-30 | 2021-08-12 | ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company | Water-soluble polymer dye with pendant chromophore |
CA3107332A1 (en) | 2018-07-22 | 2020-01-30 | Bioasis Technologies Inc. | Treatment of lymphatic metastases |
EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
US20210355468A1 (en) | 2020-05-18 | 2021-11-18 | Bioasis Technologies, Inc. | Compositions and methods for treating lewy body dementia |
US20210393787A1 (en) | 2020-06-17 | 2021-12-23 | Bioasis Technologies, Inc. | Compositions and methods for treating frontotemporal dementia |
EP4155349A1 (en) | 2021-09-24 | 2023-03-29 | Becton, Dickinson and Company | Water-soluble yellow green absorbing dyes |
WO2024007016A2 (en) | 2022-07-01 | 2024-01-04 | Beckman Coulter, Inc. | Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives |
WO2024044327A1 (en) | 2022-08-26 | 2024-02-29 | Beckman Coulter, Inc. | Dhnt monomers and polymer dyes with modified photophysical properties |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6395266B1 (en) * | 1998-04-17 | 2002-05-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
WO1981001145A1 (en) * | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
IL83966A (en) * | 1986-09-26 | 1992-03-29 | Schering Ag | Amides of aminopolycarboxylic acids and pharmaceutical compositions containing them |
US4943579A (en) * | 1987-10-06 | 1990-07-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble prodrugs of camptothecin |
US5283339A (en) * | 1988-11-23 | 1994-02-01 | California Institute Of Technology | Immobilized metal aqueous two-phase extraction and precipitation |
US6039931A (en) | 1989-06-30 | 2000-03-21 | Schering Aktiengesellschaft | Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production |
JPH06501448A (en) * | 1989-12-26 | 1994-02-17 | ノバ ファーマシューティカル コーポレイション | Anhydride prodrug composition |
JP3051145B2 (en) * | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | Novel polyethylene glycol derivative modified peptide |
US5433886A (en) * | 1992-05-07 | 1995-07-18 | Calgon Corporation | Stabilization of polyether polyamino methylene phosphonate scale inhibitors against degradation by bromine and chlorine biocides |
WO1993024476A1 (en) * | 1992-06-04 | 1993-12-09 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
GB9213077D0 (en) * | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
US5614549A (en) * | 1992-08-21 | 1997-03-25 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5756825A (en) | 1992-09-08 | 1998-05-26 | Safavy; Ahmad | Hydroxamic acid-based bifunctional chelating compounds |
WO1994009056A1 (en) * | 1992-10-14 | 1994-04-28 | Sterling Winthrop Inc. | Chelating polymers |
US5547981A (en) * | 1993-03-09 | 1996-08-20 | Enzon, Inc. | Taxol-7-carbazates |
US5454954A (en) * | 1993-09-21 | 1995-10-03 | Calgon Corporation | Scale control in metal mining circuits using polyether polyamino methylene phosphonates |
GB9320781D0 (en) * | 1993-10-08 | 1993-12-01 | Erba Carlo Spa | Polymer-bound camptothecin derivatives |
US5840900A (en) * | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5880131A (en) * | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
CA2174350A1 (en) * | 1993-10-20 | 1995-04-27 | Richard B. Greenwald | 2'- and/or 7- substituted taxoids |
US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5646159A (en) * | 1994-07-20 | 1997-07-08 | Research Triangle Institute | Water-soluble esters of camptothecin compounds |
US5672335A (en) | 1994-11-30 | 1997-09-30 | Schering Aktiengesellschaft | Use of metal complexes as liver and gallbladder X-ray diagnostic agents |
US5489589A (en) * | 1994-12-07 | 1996-02-06 | Bristol-Myers Squibb Company | Amino acid derivatives of paclitaxel |
US5679852A (en) * | 1995-06-02 | 1997-10-21 | Schering Aktiengesellschaft | Process for the production of DTPA-monoamides of the central carboxylic acid and their use as pharmaceutical agents |
US6020373A (en) * | 1995-10-20 | 2000-02-01 | Eastern Virginia Medical School | Chelate derivatives as protectors against tissue injury |
TW520293B (en) | 1995-11-22 | 2003-02-11 | Univ Johns Hopkins Med | Delivery system to enhance cellular uptake of biomolecules |
DE69939033D1 (en) | 1998-03-12 | 2008-08-14 | Nektar Therapeutics Al Corp | Process for the preparation of polymer conjugates |
-
1998
- 1998-04-17 US US09/062,305 patent/US6153655A/en not_active Expired - Lifetime
-
1999
- 1999-04-16 JP JP2000544354A patent/JP4860813B2/en not_active Expired - Fee Related
- 1999-04-16 WO PCT/US1999/008373 patent/WO1999053951A1/en active Application Filing
- 1999-04-16 US US09/293,624 patent/US6395266B1/en not_active Expired - Fee Related
- 1999-04-16 AU AU36483/99A patent/AU3648399A/en not_active Abandoned
- 1999-04-16 EP EP99918611A patent/EP1071455A4/en not_active Ceased
- 1999-04-16 CA CA2328922A patent/CA2328922C/en not_active Expired - Fee Related
-
2002
- 2002-02-06 US US10/067,930 patent/US6638499B2/en not_active Expired - Fee Related
-
2003
- 2003-08-08 US US10/638,031 patent/US20040053976A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6395266B1 (en) * | 1998-04-17 | 2002-05-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006136586A2 (en) * | 2005-06-22 | 2006-12-28 | Complex Biosystems Gmbh | N, n-bis- (2-hydroxyethyl) glycine amide as linker in polymer conjugated prodrugs |
WO2006136586A3 (en) * | 2005-06-22 | 2007-07-26 | Complex Biosystems Gmbh | N, n-bis- (2-hydroxyethyl) glycine amide as linker in polymer conjugated prodrugs |
US20100291021A1 (en) * | 2005-06-22 | 2010-11-18 | Dirk Vetter | Aliphatic prodrug linker |
AU2006260914B2 (en) * | 2005-06-22 | 2011-04-14 | Ascendis Pharma A/S | N, N-bis- (2-hydroxyethyl) glycine amide as linker in polymer conjugated prodrugs |
CN101242859B (en) * | 2005-06-22 | 2013-04-03 | 复合生物系统股份有限公司 | N,N-bis-(2-hydroxyethyl) glycine amide as linker in polymer conjugated prodrugs |
US8980242B2 (en) | 2005-06-22 | 2015-03-17 | Ascendis Pharma Gmbh | Aliphatic prodrug linker |
WO2007081596A3 (en) * | 2006-01-10 | 2007-12-13 | Enzon Pharmaceuticals Inc | High efficiency method of preparing polyalkylene oxide carboxylic acids |
US7989554B2 (en) | 2006-01-10 | 2011-08-02 | Enzon Pharmaceuticals, Inc. | Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid |
WO2012098557A1 (en) * | 2011-01-20 | 2012-07-26 | Institute Of Life Sciences | Pegylated gemcitabine derivative and process for preparing the same |
US10392611B2 (en) | 2013-05-30 | 2019-08-27 | Duke University | Polymer conjugates having reduced antigenicity and methods of using the same |
US10364451B2 (en) | 2013-05-30 | 2019-07-30 | Duke University | Polymer conjugates having reduced antigenicity and methods of using the same |
US11103593B2 (en) | 2013-10-15 | 2021-08-31 | Seagen Inc. | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
US10385115B2 (en) | 2015-03-26 | 2019-08-20 | Duke University | Fibronectin type III domain-based fusion proteins |
US11458205B2 (en) | 2015-08-04 | 2022-10-04 | Duke University | Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
US11229708B2 (en) | 2015-12-04 | 2022-01-25 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
CN109152818A (en) * | 2015-12-21 | 2019-01-04 | 杜克大学 | Antigenic polymer conjugates and its application method with reduction |
WO2017112826A3 (en) * | 2015-12-21 | 2017-08-31 | Duke University | Polymer conjugates having reduced antigenicity and methods of using the same |
WO2017112825A3 (en) * | 2015-12-21 | 2017-08-31 | Duke University | Polymer conjugates having reduced antigenicity and methods of using the same |
US11844839B2 (en) | 2016-03-25 | 2023-12-19 | Seagen Inc. | Process for the preparation of pegylated drug-linkers and intermediates thereof |
US11467156B2 (en) | 2016-06-01 | 2022-10-11 | Duke University | Nonfouling biosensors |
US11135301B2 (en) | 2016-09-14 | 2021-10-05 | Duke University | Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs |
US11155584B2 (en) | 2016-09-23 | 2021-10-26 | Duke University | Unstructured non-repetitive polypeptides having LCST behavior |
US11648200B2 (en) | 2017-01-12 | 2023-05-16 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
US11730822B2 (en) | 2017-03-24 | 2023-08-22 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
US11554097B2 (en) | 2017-05-15 | 2023-01-17 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
US11680083B2 (en) | 2017-06-30 | 2023-06-20 | Duke University | Order and disorder as a design principle for stimuli-responsive biopolymer networks |
US11649275B2 (en) | 2018-08-02 | 2023-05-16 | Duke University | Dual agonist fusion proteins |
US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
US11965164B2 (en) | 2019-07-12 | 2024-04-23 | Duke University | Amphiphilic polynucleotides |
Also Published As
Publication number | Publication date |
---|---|
EP1071455A1 (en) | 2001-01-31 |
US6395266B1 (en) | 2002-05-28 |
CA2328922A1 (en) | 1999-10-28 |
US6153655A (en) | 2000-11-28 |
AU3648399A (en) | 1999-11-08 |
WO1999053951A9 (en) | 2000-10-05 |
CA2328922C (en) | 2010-06-15 |
WO1999053951A1 (en) | 1999-10-28 |
US6638499B2 (en) | 2003-10-28 |
JP4860813B2 (en) | 2012-01-25 |
EP1071455A4 (en) | 2002-08-14 |
US20020103259A1 (en) | 2002-08-01 |
JP2002512265A (en) | 2002-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6395266B1 (en) | Terminally-branched polymeric linkers and polymeric conjugates containing the same | |
US6303569B1 (en) | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents | |
US6251382B1 (en) | Biodegradable high molecular weight polymeric linkers and their conjugates | |
US6011042A (en) | Acyl polymeric derivatives of aromatic hydroxyl-containing compounds | |
CA2312975C (en) | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents | |
US5965566A (en) | High molecular weight polymer-based prodrugs | |
US6777387B2 (en) | Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same | |
EP1362053B1 (en) | Terminally-branched polymeric linkers and polymeric conjugates containing the same | |
US6824766B2 (en) | Biodegradable high molecular weight polymeric linkers and their conjugates | |
WO1998007713A1 (en) | High molecular weight polymer-based prodrugs | |
CA2336663C (en) | Coumarin and related aromatic-based polymeric prodrugs | |
US20020161052A1 (en) | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |